The small, Lexington, MA-based biotech Curis is jumping onto the increasingly popular immuno-oncology bandwagon, handing over a chunk of its stock and promising more than $100 million in milestones to Bangalore-based Aurigene if they can successfully take a small molecule approach to the cancer field and advance a new program through preclinical and clinical development and on into the market. And it's getting a second targeted small molecule for cancer that is intended to hit IRAK4.
Lexington, MA-based Curis says the FDA has lifted the partial clinical hold on CUDC-427, which was instituted after the death of a patient in a Phase I study of solid tumors and lymphoma.
A year after Curis agreed to pay Genentech $9.5 million upfront to license the early-stage cancer therapy recoded as CUDC-427 and borrowed $30 million to launch its own study, the FDA has clamped a partial clinical hold on the program following the death of one patient taking the drug.
And Curis immediately spent a big chunk of that to in-license an experimental cancer therapy from its colleagues at Genentech, flipping the usual order of deal-making as the little biotech paid the giant Roche subsidiary a small upfront to gain development rights.
The German biotech 4SC AG says its experimental drug resminostat extended overall survival among advanced liver cancer patients by 8 months in Phase II when combined with Bayer's Nexavar.
Roche ($RHHBY) and Genentech won a landmark approval for the cancer drug vismodegib today. After gaining significant efficacy data from a Phase II study on basal cell carcinoma, the drug giant not
Shares of Germany's 4SC ($VSC) surged 35% after investigators reported promising mid-stage data for the cancer drug resminostat, an HDAC inhibitor, in difficult-to-treat patients with advanced liver
The Leukemia & Lymphoma Society (LLS) has handed Lexington, MA-based Curis $4 million to support early development of two of the company's drugs for blood cancers. Curis' drug, CUDC-907, is an
Armed with positive data from a pivotal Phase II trial, Lexington, MA-based Curis is waiting for its partner Roche to begin its long-awaited pitch to gain FDA approval for a new treatment for
Roche and Genentech have posted a fresh set of promising mid-stage data on vismodegib, a cancer drug it's collaborating on with Lexington, MA-based Curis. In what investigators describe as a pivotal